Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
21.8%/yr
±5.2% · revenue growth to justify current price
FCF-Based Reverse DCF
18.4%/yr
±3.2% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
Edwards delivered solid FY2025 with 11.5% revenue growth driven by TMTT (+56%) while TAVR matures (+9%). Strong balance sheet with $4.2B cash, $1.6B OCF. Key concerns: litigation expenses surged to $3...